NeuroPace, Inc. SEC filings document the company's medical-device business, Nasdaq-listed common stock and public-company reporting obligations for the RNS System epilepsy therapy. Form 8-K reports cover operating results, financial condition, corporate updates, material agreements, clinical or regulatory disclosures, and executive or compensation-related events.
Proxy filings describe NeuroPace governance matters, including annual meeting proposals, director elections, auditor ratification and stockholder voting mechanics. The filing record also provides formal disclosure on capital structure, officer transitions, separation or consulting arrangements, and risk areas associated with commercialization, clinical evidence and regulatory oversight of neurostimulation devices.
NeuroPace, Inc. reported strong first quarter 2026 growth and raised its full-year revenue outlook. Non-GAAP revenue (excluding DIXI Medical) rose 20.1% to $22.0 million from $18.3 million a year earlier, driven by RNS System revenue of $21.7 million, up 19.5%.
Non-GAAP gross margin was 82.5%, while GAAP net loss was ($6.7) million. On a non-GAAP basis, loss from operations improved to ($3.3) million from ($4.1) million, and non-GAAP net loss narrowed to ($4.4) million from ($5.6) million.
For full year 2026, NeuroPace now expects revenue between $99 million and $101 million, implying 21%–23% underlying RNS growth, and reiterates non-GAAP gross margin of 81.5%–82.5% and non-GAAP operating expenses of $90–$92 million. Adjusted EBITDA is guided to a loss of ($8.5)–($9.5) million. The company completed the FDA mid-cycle review for its NAUTILUS PMA supplement and plans to report DIXI Medical as discontinued operations starting in the second quarter.
NeuroPace, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 5, 2026 at 10:30 a.m. Pacific time. Only holders of the 33,950,449 shares of common stock outstanding as of April 9, 2026 may vote, one vote per share.
Stockholders are asked to elect two Class II directors, Lisa Andrade and Scott Huennekens, to serve until the 2029 annual meeting, and to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026. The Board recommends voting for all nominees and for auditor ratification.
The proxy describes NeuroPace’s board structure, committee memberships, independence determinations, executive and director compensation, equity incentive and cash bonus plans, and severance and change in control protections for senior officers, including CEO Joel Becker, CFO Patrick Williams, and CMO Martha Morrell.
NeuroPace Inc’s Chief Medical Officer Martha Morrell reported a routine share transfer related to taxes rather than a market trade. On March 24, 2026, 1,341 shares of common stock were withheld by the company at $13.27 per share to cover tax obligations from the vesting of a restricted stock unit award. After this tax-withholding disposition, she directly holds 47,283 common shares, indicating she retains the substantial majority of her equity position. This event reflects standard tax treatment of equity compensation, not an open-market purchase or sale.
Geiger Uri reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Uri Geiger received 913 shares of Common Stock as a grant on March 20, 2026 at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly retainer fees. Following the grant, he holds 14,858 shares directly and an additional 4,432,948 shares indirectly through Accelmed Partners II LP, where he has sole voting and dispositive power over the held shares.
LACOB JOSEPH reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Joseph Lacob received a grant of 865 shares of common stock at $13.00 per share as part of non-employee director compensation in lieu of quarterly retainer fees. Following this award, he holds 14,754 shares directly, plus indirect holdings through Lacob Ventures LLC and LCT18 Investments.
Kumar Rakhi reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Rakhi Kumar received an equity grant of 1,153 shares of Common Stock at $13.00 per share. The shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees, bringing Kumar’s direct holdings to 19,160 shares.
Fischer Frank M reported acquisition or exercise transactions in this Form 4 filing.
NeuroPace Inc director Frank M. Fischer received 1,826 shares of Common Stock as a grant at $13.00 per share. These shares were issued under the company’s non-employee director compensation policy in lieu of quarterly cash retainer fees.
Following this stock compensation, Fischer directly owns 595,177 shares, indicating this was a routine, compensation-related equity award rather than an open-market purchase or sale.
NeuroPace Inc’s chief medical officer Martha Morrell reported two recent stock transactions. On December 15, 2025, she completed an open-market sale of 25,000 shares of common stock at a weighted average price of $15.97 per share under a Rule 10b5-1 trading plan.
On March 3, 2026, 1,340 shares of common stock were withheld to cover tax obligations tied to the vesting of a restricted stock unit award, at a price of $13.83 per share. After these transactions, she directly held 48,624 shares of NeuroPace common stock.
NeuroPace Inc’s CEO Joel Becker reported a tax-related share withholding. On March 3, 2026, 5,023 shares of common stock were disposed of at $13.83 per share to satisfy tax withholding obligations tied to a restricted stock unit vesting. After this withholding, Becker directly owns 96,937 shares of NeuroPace common stock.